Down 16%, Should You Buy the Dip on Alphabet?
By zooming out, it becomes obvious that Alphabet (NASDAQ: GOOGL)(NASDAQ: GOOG) has been a huge winner for investors. Shares have surged 144% in the past five years, and they're up an impressive 525% just in the last decade. Becoming a dominant internet enterprise has resulted in some very happy shareholders.
But as of this writing on May 28, this top technology stock trades 16% below its high, which was reached on Feb. 4. Should you take advantage of the market's pessimism and buy the dip on Alphabet right now?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
Is AI a risk or an opportunity?
With the proliferation of generative artificial intelligence (AI) tools in recent years, investors have rightfully been concerned that Alphabet's crown jewel, Google Search, that represented 56% of sales in the first quarter, would be disrupted. That's because it's believed that users would turn more to AI when seeking out information on a variety of topics, pulling traffic away from Google Search. In turn, this could negatively impact advertising revenue.
So far, it appears these fears are overblown. First off, Google Search still commands a whopping 90% of global market share when it comes to search engines. Additionally, Google Search saw revenue increase 10% year over year in Q1. And that $50.7 billion sales figure is up 28% from the same period three years ago.
Lastly, it's worth pointing out that Alphabet isn't resting on its laurels. The company has clearly made AI a top priority. At its annual Google I/O developer conference in May, Alphabet did not disappoint. A notable 100 updates were announced, with new AI features coming across the board.
Alphabet is already finding ways to make money from AI. "For AI Overviews, overall, we continue to see monetization at approximately the same rate," Chief Business Officer Philipp Schindler said on the Q1 2025 earnings call when comparing Overviews to traditional search.
And when it comes to advertising customers, AI is helping them create more effective marketing campaigns that can increase return on spend and enhance targeting capabilities.
In Q1, Alphabet generated $34.5 billion in net income. This puts it in an enviable position to keep plowing sizable financial resources into AI initiatives to bolster its competitive standing.
Alphabet's economic moat
Alphabet's wide economic moat is a key factor that highlights just how outstanding of a business this really is. The company benefits from powerful network effects within Search and YouTube. There are invaluable, intangible assets at play, like the Alphabet and Google brands, unrivaled technological know-how, and the ability to collect unbelievable amounts of data that can directly impact strategic decisions.
There is also a cost advantage, particularly with Google Cloud. The platform requires huge fixed costs to build out the infrastructure. This explains why the segment was unprofitable for a long time. However, now that revenue has scaled up to $49 billion on an annualized run-rate in Q1, Google Cloud is boosting the bottom line. Operating income totaled $2.2 billion in the first three months of 2025.
Google Cloud's customers also deal with high switching costs. Once they onboard and start to depend on Alphabet as its mission-critical IT partner, it makes sense why they would be inclined to stay put unless they want to cause potential operational disruptions.
Trading at a discount to the market
Investors will notice that Alphabet's valuation is too hard to ignore. Shares trade at a price-to-earnings (P/E) ratio of 19.2. This is a discount to the S&P 500 Index, which just doesn't seem warranted given the quality of this business. And of all the " Magnificent Seven" stocks, Alphabet is the cheapest.
Finding such a great deal in the stock market can make investors think that they're overlooking something. However, it's best not to overanalyze the situation. Alphabet is a smart buy while on the dip.
Should you invest $1,000 in Alphabet right now?
Before you buy stock in Alphabet, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!*
Now, it's worth noting Stock Advisor 's total average return is979% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Global Net Lease Appoints Robert Kauffman as Board Chair
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Global Net Lease, Inc. (NYSE: GNL) ("GNL" or the "Company") today announced the appointment of Robert Kauffman as Non-Executive Chairperson of its Board of Directors (the "Board"), effective immediately. Mr. Kauffman succeeds Sue Perrotty, who resigned from her position as Non-Executive Chairperson but will continue to serve on the Board as an independent director. Mr. Kauffman, a Co-Founder and former member of the Board of Directors of Fortress Investment Group, joined the GNL Board in March 2024. "We are excited that Rob Kauffman has become Chair of our Board at this transformative time for GNL," said Michael Weil, CEO of GNL. "Since joining the Board, Rob has played an active role in our strategic initiatives – including our multi-tenant asset sale – and has added tremendous value through his extensive real estate and capital markets experience at Fortress, UBS and BlackRock. As we move toward a new era for GNL as a pure-play single-tenant net lease company, which we believe positions us to deliver additional value for shareholders, we look forward to benefiting from his leadership for years to come." "Our entire Board thanks Sue Perrotty for her many years of dedication and leadership as Board Chair through a period of considerable evolution for GNL," Mr. Weil added. "I am honored to step into this new role at such an important time for GNL," said Mr. Kauffman. "GNL has taken significant steps over the last year to streamline its portfolio, strengthen its balance sheet, and enhance financial flexibility. I look forward to continuing to work closely with my fellow directors and GNL's seasoned management team to capitalize on our strong momentum." About Global Net Lease, Inc. Global Net Lease, Inc. (NYSE: GNL) is a publicly traded internally managed real estate investment trust that focuses on acquiring and managing a global portfolio of income producing net lease assets across the U.S., and Western and Northern Europe. Additional information about GNL can be found on its website at Important Notice The statements in this press release that are not historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. The words such as "may," "will," "seeks," "anticipates," "believes," "expects," "estimates," "projects," "potential," "predicts," "plans," "intends," "would," "could," "should" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties and other factors, many of which are outside of the Company's control, which could cause actual results to differ materially from the results contemplated by the forward-looking statements. These risks and uncertainties include the risks that any potential future acquisition or disposition (including the proposed closing of the encumbered properties portion of the multi-tenant portfolio) by the Company is subject to market conditions, capital availability and timing considerations and may not be identified or completed on favorable terms, or at all. Some of the risks and uncertainties, although not all risks and uncertainties, that could cause the Company's actual results to differ materially from those presented in the Company's forward-looking statements are set forth in the "Risk Factors" and "Quantitative and Qualitative Disclosures about Market Risk" sections in the Company's Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and all of its other filings with the U.S. Securities and Exchange Commission, as such risks, uncertainties and other important factors may be updated from time to time in the Company's subsequent reports. Further, forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise any forward-looking statement to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, unless required by law.
Globe and Mail
24 minutes ago
- Globe and Mail
Goliath Resources Announces Concurrent Non-Brokered Private Placement of Charity Flow-Through Shares Following Previously Announced 'Bought Deal' Offering For Combined Gross Proceeds Total Up To C$24,065,200
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (Frankfurt: B4IF) (the " Company" or " Goliath") is pleased to announce that, in response to overwhelming institutional demand following the announcement of a proposed 'bought deal' private placement for gross proceeds of C$20,002,700 (see the news release of the Company dated May 29, 2025) (the ' Bought Deal Offering '), the Company intends to complete a concurrent non-brokered private placement on similar terms whereby it proposes to issue up to 1,281,545 common shares of the Company (the ' Charity Flow-Through Shares ') at a price of C$3.17 per Charity Flow-Through Share for gross proceeds of up to approximately C$4,062,500 (the ' Concurrent Offering '). The Charity Flow-Through Shares will qualify as 'flow-through shares' as defined in subsection 66(15) of the Income Tax Act (Canada) (the ' Tax Act '). The Concurrent Offering is intended to accommodate additional demand for the Charity Flow-Through Shares, and provides the Company with further flexibility in allocating Charity Flow-Through Shares to investors. In aggregate, the Company anticipates raising up to C$24,065,200 in total gross proceeds under the Bought Deal Offering and the Concurrent Offering. In consideration for the services provided to the Company in connection with the Concurrent Offering, certain finders will be entitled to receive a cash commission equal to 6.0% of the gross proceeds raised under the Concurrent Offering and such number of common share purchase warrants (' Finder's Warrants ') as is equal to 6.0% of the number of Charity Flow-Through Shares sold under the Concurrent Offering. Each Finder's Warrant will entitle the holder thereof to acquire one common share of the Company at a price of C$1.95 for a period of 24 months following the closing of the Concurrent Offering. The cash commission will not be paid from the gross proceeds of the Concurrent Offering and will be paid using the Company's existing cash on hand. The Concurrent Offering is expected to close on or about June 16, 2025 (the ' Closing Date '), and is subject to certain conditions including the receipt of all necessary approvals such as the approval of the TSX Venture Exchange (the " Exchange"). The Company will use the gross proceeds of the Concurrent Offering to incur Qualifying Expenditures (as defined here) on the Company's flagship Golddigger-Surebet Gold Project, located in British Columbia, Canada. The gross proceeds from the Charity Flow-Through Shares will be used to incur exploration expenses that qualify as "Canadian exploration expenses" as defined in subsection 66.1(6) of the Tax Act, "flow-through mining expenditures" as defined in subsection 127(9) of the Tax Act for purposes of the mineral exploration tax credit, and for individual subscribers resident in British Columbia, "BC flow-through mining expenditures" as defined in subsection 4.721(1) of the Income Tax Act (British Columbia) (the ' Qualifying Expenditures '). Such expenses will be incurred on or before December 31, 2026, and renounced to the subscribers with an effective date no later than December 31, 2025. The "BC mining flow-through share tax credit" allows individual residents of British Columbia who invest in flow-through shares to claim a provincial non-refundable tax credit in an amount equal to 20% of such subscriber's "BC flow-through mining expenditures." The Charity Flow-Through Shares, the Finder's Warrants and common shares that will be issuable upon the exercise of the Finder's Warrants (if any) will be issued pursuant to available exemptions under National Instrument 45-106 - Prospectus Exemptions, and will be subject to a hold period expiring four months and one day following the Closing Date. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " 1933 Act") or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available. About Goliath Resources Limited Goliath is an explorer of precious metals projects in the prolific Golden Triangle of northwestern British Columbia. All of its projects are in high quality geological settings and geopolitical safe jurisdictions amenable to mining in Canada. Goliath is a member and active supporter of CASERM which is an organization that represents a collaborative venture between Colorado School of Mines and Virginia Tech. Goliath's key strategic cornerstone shareholders include Crescat Capital, McEwen Mining Inc. (NYSE: MUX) (TSX: MUX), Mr. Rob McEwen, a Global Commodity Group based in Singapore, Mr. Eric Sprott and Mr. Larry Childress. For more information please contact: Goliath Resources Limited Mr. Roger Rosmus Founder and CEO Tel: +1.416.488.2887 roger@ This press release contains statements that constitute 'forward-looking information' (' forward-looking information ') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. Forward-looking statements in this news release include statements regarding the Concurrent Offering (including the completion of the Concurrent Offering on the terms and timeline as announced or ats all, the tax treatment of the Charity Flow-Through Shares, the timing to incur and renounce all Qualifying Expenditures in favour of the subscribers, and the use of proceeds of the Concurrent Offering), and the Company's ability to obtain all regulatory approvals, including the approval of the Exchange. In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Such factors include but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting the Company's business and results of operations; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.
Globe and Mail
25 minutes ago
- Globe and Mail
NanoViricides (NNVC) to Unveil ‘Escape-Proof' Antiviral Platform at Major Biotech Convention
NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs. NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat viral infections—potentially creating the first "empiric antiviral therapy" similar to how antibiotics work for bacterial infections. A Major Platform for a Breakthrough Company NanoViricides, Inc. (NYSE American: NNVC) has announced it will be presenting on Monday, June 16th, at 2:30pm at the BIO International Convention 2025 in Boston, MA. This isn't just any conference—the BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe. Event Details: The Revolutionary Science Behind NNVC What makes NanoViricides particularly compelling is their unique approach to antiviral therapy. NV-387 is a revolutionary broad-spectrum drug candidate designed to mimic host-side features that the virus particle uses as the first landing site in order to mount a cellular infection. The implications are staggering: an estimated 90-95% of human pathogens utilize the same common landing feature that is mimicked by NV-387, giving the drug its extremely broad antiviral spectrum. Why This Matters: The "Escape-Proof" Advantage Traditional antivirals face a critical weakness—viruses mutate and develop resistance. NNVC's approach is fundamentally different. The virus cannot escape NV-387 even as it changes in the field, because the virus continues to use the sulfated proteoglycan features for attachment despite all changes. This represents a paradigm shift from existing vaccines, antibodies, and small chemical anti-viral modalities that are all readily defeated by viruses by relatively small changes, often in single viral proteins. Game-Changing Clinical Results The company's lead drug candidate has already demonstrated remarkable efficacy. NV-387 was found to be highly effective against the "tripledemic" respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. In all of these cases, NV-387 was substantially superior to existing drugs. The Path to "Empiric Antiviral Therapy" Perhaps most exciting is NNVC's vision for the future of antiviral treatment. NV-387 is expected to become an "emperic therapy" for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections. NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. This means doctors could prescribe antiviral treatment immediately upon seeing a patient with viral symptoms, without waiting for specific test results—a breakthrough that could save countless lives. Diverse Pipeline with Massive Market Potential NNVC isn't a one-trick pony. Their pipeline includes: The overall market size of NV-387 indications is estimated to be well in excess of $10 billion. Beyond Antivirals: Platform Technology Opportunities The company's nanoviricide platform extends beyond just antiviral applications. The technology enables: What to Watch at BIO Convention Dr. Diwan will be providing updates on the company's drug pipeline and discussing platform technologies available for licensing. Dr. Diwan will also be available for meetings in the BIO Partnering™ match-making platform during the Convention from June 16th through June 19th, 2025. This presents significant partnership and licensing opportunities, potentially accelerating development timelines and providing non-dilutive funding sources. The Bottom Line NanoViricides represents a potentially transformative approach to antiviral therapy. Their presentation at BIO Convention offers a crucial opportunity to showcase their technology to potential partners and investors. With their lead drug candidate moving toward Phase II trials and a platform technology with applications beyond antivirals, NNVC could be positioned at the forefront of a new era in viral disease treatment. The June 16th presentation will be a key catalyst to watch, potentially providing insights into partnership opportunities, development timelines, and the company's strategic direction. For investors interested in revolutionary biotech plays, NNVC deserves serious consideration—while keeping in mind the inherent risks of clinical-stage pharmaceutical development. Some of the other biotech stocks to keep on radar include Vertex Pharmaceuticals (NASDAQ: VRTX), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Summit Therapeutics Inc. (NASDAQ: SMMT) and Moderna, Inc. (NASDAQ: MRNA). Disclaimer: This analysis is for informational purposes only and should not be considered as investment advice. Always conduct your own research and consult with financial advisors before making investment decisions. Clinical-stage pharmaceutical companies carry significant risks, and there can be no assurance of successful drug development or regulatory approval. This blog post is for informational purposes only and does not constitute financial advice or an endorsement of COEP or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated one thousand five hundred dollars by a 3rd party EDM Media for content distribution services on NNVC for June 2nd, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like 'believes,' 'anticipates,' 'estimates,' 'expects,' 'projects,' 'intends,' or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person's use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions. Source: Media Contact Company Name: UsaStockReport Contact Person: Ash K Email: editor@ City: Frisco State: Texas Country: United States Website:
